ERBB2 and neoplasm: As shown in Figure 5C, this combination significantly improved the therapeutic effects of scFvNLDC-145-HER2 vaccine; at the end of experiment, 80% (16/20) mice rejected the established tumor and remaining 4 (20%) mice had stably small tumors (~30 mm3).